We are live on ! Find out more
MRVI icon

Maravai LifeSciences
MRVI

118 hedge funds and large institutions have $2.73B invested in Maravai LifeSciences in 2020 Q4 according to their latest regulatory filings, with 118 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1,490% more call options, than puts

Call options by funds: $5.21M | Put options by funds: $328K

100.83% more ownership

Funds ownership: 0% → 100.83% (+101%)

Holders
118
Holders Change
+118
Holders Change %
–
% of All Funds
2.09%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.09%
New
118
Increased
–
Reduced
–
Closed
–
Calls
$5.21M
Puts
$328K
Net Calls
+$4.89M
Net Calls Change
+$4.89M

Top Buyers

Rank Fund Capital Flow
1
DCP
D1 Capital Partners
New York
+$165M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$159M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$131M
4
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$118M
5
JP Morgan Chase
JP Morgan Chase
New York
+$115M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
76
Moore Capital Management
New York
$793K +$787K +28,257 New
ECM
77
ExodusPoint Capital Management
New York
$776K +$770K +27,650 New
Morgan Stanley
78
Morgan Stanley
New York
$744K +$739K +26,526 New
EA
79
Emerald Advisers
Pennsylvania
$720K +$714K +25,656 New
SG Americas Securities
80
SG Americas Securities
New York
$673K +$668K +24,000 New
TEE
81
Tibra Equities Europe
United Kingdom
$673K +$668K +24,000 New
Ameriprise
82
Ameriprise
Minnesota
$622K +$618K +22,178 New
MFS
83
Mirabella Financial Services
United Kingdom
$593K +$589K +21,140 New
PCM
84
Pentwater Capital Management
Florida
$589K +$585K +21,000 New
SSA
85
Schonfeld Strategic Advisors
New York
$580K +$576K +20,695 New
Federated Hermes
86
Federated Hermes
Pennsylvania
$561K +$557K +20,000 New
MA
87
MYDA Advisors
New York
$561K +$557K +20,000 New
Legal & General Group
88
Legal & General Group
United Kingdom
$533K +$530K +19,042 New
Sumitomo Mitsui Trust Group
89
Sumitomo Mitsui Trust Group
Japan
$517K +$513K +18,422 New
VF
90
Virtu Financial
New York
$456K +$453K +16,266 New
Wellington Management Group
91
Wellington Management Group
Massachusetts
$452K +$449K +16,116 New
Cerity Partners
92
Cerity Partners
New York
$422K +$419K +15,057 New
CI Investments Inc
93
CI Investments Inc
Ontario, Canada
$397K +$394K +14,137 New
PFA
94
Paradigm Financial Advisors
Missouri
$365K +$363K +13,020 New
HSBC Holdings
95
HSBC Holdings
United Kingdom
$333K +$330K +11,841 New
Stifel Financial
96
Stifel Financial
Missouri
$327K +$325K +11,658 New
Qube Research & Technologies (QRT)
97
Qube Research & Technologies (QRT)
United Kingdom
$274K +$272K +9,751 New
Envestnet Asset Management
98
Envestnet Asset Management
Illinois
$232K +$230K +8,261 New
CIBC Asset Management
99
CIBC Asset Management
Ontario, Canada
$230K +$229K +8,210 New
EMFAT
100
Emerald Mutual Fund Advisers Trust
Pennsylvania
$79K +$78.1K +2,803 New
1 2 3
4
5

MRVI Hedge Fund Activity: Q4 2020 in Review

118 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2020, worth a combined $2.73B.

Buyers outnumbered sellers: 118 funds opened new MRVI positions and 0 closed out — a net gain of 118 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was D1 Capital Partners, opening a new position worth an estimated $165M.

  • 118 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $2.73B of Maravai LifeSciences stock for Q4 2020.
  • 118 funds opened new Maravai LifeSciences positions in Q4 2020 and 0 closed out, a net change of +118 holders.
  • The largest Maravai LifeSciences buyer in Q4 2020 was D1 Capital Partners, an estimated $165M added.

Based on aggregated 13F filings for Q4 2020.